The Tumor Suppressor BAP1 Regulates the Hippo Pathway in Pancreatic Ductal Adenocarcinoma
Ho-June Lee, Trang Pham, Matthew T. Chang, Dwight F. Barnes, Allen G. Cai, Rajkumar Noubade, Klára Tótpál, Xu Chen, Christopher Tran, Thijs J. Hagenbeek, Xiumin Wu, Jeff Eastham-Anderson, Janet Tao, Wyne P. Lee, Boris C. Bastian, Michele Carbone, Joshua D. Webster, Anwesha Dey
Abstract
Abstract The deubiquitinating enzyme BAP1 is mutated in a hereditary cancer syndrome with a high risk for mesothelioma and melanocytic tumors. Here, we show that pancreatic intraepithelial neoplasia driven by oncogenic mutant KrasG12D progressed to pancreatic adenocarcinoma in the absence of BAP1. The Hippo pathway was deregulated in BAP1-deficient pancreatic tumors, with the tumor suppressor LATS exhibiting enhanced ubiquitin-dependent proteasomal degradation. Therefore, BAP1 may limit tumor progression by stabilizing LATS and thereby promoting activity of the Hippo tumor suppressor pathway. Significance: BAP1 is mutated in a broad spectrum of tumors. Pancreatic Bap1 deficiency causes acinar atrophy but combines with oncogenic Ras to produce pancreatic tumors. BAP1-deficient tumors exhibit deregulation of the Hippo pathway. See related commentary by Brekken, p. 1624